Menlo Therapeutics

Menlo Therapeutics is a clinical late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for refractory chronic cough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. Show more